The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Acalabrutinib receives approval in Europe for the treatment of CLL
On November 9, 2020, the next generation Bruton’s tyrosine kinase (BTK) inhibitor, acalabrutinib, was approved in the European Union for the treatment of adult patients with chronic lymphocytic leukemia (CLL).
Positive results from both the ELEVATE-TN and ASCEND studies, evaluating acalabrutinib in patients with treatment-naïve and relapsed/refractory (R/R) CLL, respectively, formed the basis of this approval. Acalabrutinib formerly received a positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) in July 2020, and U.S. Food and Drug Administration (FDA) approval for the treatment of both CLL and small lymphocytic lymphoma in November 2019.
Refinement of BTK inhibitor therapy with next generation agents like acalabrutinib promise to improve patient quality of life in the CLL setting, and this approval represents a step in the right direction to achieving a tolerable, chemotherapy-free option for patients with both treatment-naïve and R/R disease.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content